Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ:AMLX
Want to see AMLX full AI Analyst Report?
AMLX Stock Chart & Stats
$18.36
-$0.14(-3.78%)
At close: 4:00 PM EST
$18.36
-$0.14(-3.78%)
Day’s Range― - ―
52-Week Range$4.80 - $18.61
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.30M
Market Cap
$1.74B
Enterprise Value$1.04B
Total Cash (Recent Filing)$279.77M
Total Debt (Recent Filing)$5.63M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 06, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding111,186,320
10 Day Avg. Volume1,591,983
30 Day Avg. Volume1,298,043
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-51.69
Enterprise Value/Ebitda-7.07
Forecast
1Y Price Target
$24.86Price Target Upside35.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage & Sizable Equity CushionThe company’s minimal debt and a positive equity base (~$273M TTM) provide structural financial flexibility. Low leverage reduces refinancing and interest-rate risks, preserves optionality to fund clinical programs, and gives a multi-quarter cushion against setbacks without immediate reliance on dilutive financing.
Cash Runway Into 2028A reported cash balance near $280M with management-asserted runway into 2028 is a durable operational advantage: it supports completion of the pivotal LUCIDITY readout, NDA preparation, and continued R&D and commercial buildout without near-term capital raises, assuming execution remains on plan.
Pivotal Phase III Enrollment & Regulatory MomentumCompleting enrollment in a 90%-powered pivotal trial and having Breakthrough designation plus active NDA drafting materially elevates the probability of a compressed regulatory path. This structural progress de-risks timeline execution vs earlier-stage programs and positions the company to potentially commercialize if results are positive.
Bears Say
Sustained High Cash BurnPersistent negative operating and free cash flow at ~-$120M TTM materially erodes financial flexibility over time. If clinical timelines slip or commercialization is delayed, the company may need to raise capital, increasing dilution risk and constraining long-term R&D and commercial investment decisions.
Sharp Revenue DeteriorationA collapse from ~$381M to $87M then to $0 indicates loss of sustainable commercial revenue and highlights reliance on future approvals. Structurally, the company’s operating model now depends on successful clinical-to-commercial conversion rather than existing product cash flow, increasing execution risk.
Binary Dependence On LUCIDITY OutcomeThe company’s near-to-medium term valuation and commercial strategy hinge on a single pivotal readout. This binary clinical/regulatory concentration creates sustained downside risk: a negative or inconclusive outcome would materially impair revenue prospects, runway assumptions, and planned commercial investments.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals, Inc.’s price range in the past 12 months?
Amylyx Pharmaceuticals, Inc. lowest stock price was $4.80 and its highest was $18.61 in the past 12 months.
What is Amylyx Pharmaceuticals, Inc.’s market cap?
Amylyx Pharmaceuticals, Inc.’s market cap is $1.74B.
When is Amylyx Pharmaceuticals, Inc.’s upcoming earnings report date?
Amylyx Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 44 days.
How were Amylyx Pharmaceuticals, Inc.’s earnings last quarter?
Amylyx Pharmaceuticals, Inc. released its earnings results on May 07, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.338 by -$0.032.
Is Amylyx Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Amylyx Pharmaceuticals, Inc. pay dividends?
Amylyx Pharmaceuticals, Inc. pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals, Inc. dividends here
What is Amylyx Pharmaceuticals, Inc.’s EPS estimate?
Amylyx Pharmaceuticals, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Amylyx Pharmaceuticals, Inc. have?
Amylyx Pharmaceuticals, Inc. has 111,186,320 shares outstanding.
What happened to Amylyx Pharmaceuticals, Inc.’s price movement after its last earnings report?
Amylyx Pharmaceuticals, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.338. Following the earnings report the stock price went down -5.355%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in AMLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amylyx Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.86 (35.39% Upside)
$24.86 (35.39% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 307.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
207.25%
12-Months-Change
Fundamentals
Return on Equity
-55.68%
Trailing 12-Months
Asset Growth
33.65%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
AMLX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational execution: pivotal Phase III LUCIDITY enrollment completed and on track for a Q3 2026 top-line readout, active NDA preparation, clear commercial planning (including an EAP for up to 250 patients), and multiple pipeline programs advancing (AMX0318 IND-enabling work, AMX0035 longer-term data, AMX0114 cohort progress). Financially, while the company has a cash position of $279.8M with runway into 2028, cash declined ~11.7% year-over-year and operating expenses increased (total operating expenses +16% YoY; R&D +24.9% YoY), driven by development and milestone payments—risks remain tied to the upcoming LUCIDITY result and the need to convert clinical success into regulatory approval and commercial uptake.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$24.86
▲(35.39% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
8.03% Insiders
23.95% Mutual Funds
47.88% Other Institutional Investors
4.75% Public Companies and
Individual Investors